| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| J Guindon, A G Hohman. Cannabinoid CB2 receptors: a therapeutic target for the treatment of inflammatory and neuropathic pain. British journal of pharmacology. vol 153. issue 2. 2008-04-02. PMID:17994113. |
cannabinoid cb2 receptors: a therapeutic target for the treatment of inflammatory and neuropathic pain. |
2008-04-02 |
2023-08-12 |
mouse |
| J Guindon, A G Hohman. Cannabinoid CB2 receptors: a therapeutic target for the treatment of inflammatory and neuropathic pain. British journal of pharmacology. vol 153. issue 2. 2008-04-02. PMID:17994113. |
cannabinoids suppress behavioural responses to noxious stimulation and suppress nociceptive transmission through activation of cb1 and cb2 receptor subtypes. |
2008-04-02 |
2023-08-12 |
mouse |
| J Guindon, A G Hohman. Cannabinoid CB2 receptors: a therapeutic target for the treatment of inflammatory and neuropathic pain. British journal of pharmacology. vol 153. issue 2. 2008-04-02. PMID:17994113. |
here, we review behavioural, neurochemical and electrophysiological data, which identify cannabinoid cb2 receptors as a therapeutic target for treating pathological pain states with limited centrally, mediated side effects. |
2008-04-02 |
2023-08-12 |
mouse |
| I Bab, A Zimme. Cannabinoid receptors and the regulation of bone mass. British journal of pharmacology. vol 153. issue 2. 2008-04-02. PMID:18071301. |
osteoblasts, the bone forming cells, and osteoclasts, the bone resorbing cells, produce the endocannabinoids anandamide and 2-arachidonoylglycerol and express cb2 cannabinoid receptors. |
2008-04-02 |
2023-08-12 |
mouse |
| Estera Páldyová, E Bereczki, M Sántha, T Wenger, Anna Borsodi, S Benyh. Altered gene expression and functional activity of opioid receptors in the cerebellum of CB1 cannabinoid receptor knockout mice after acute treatments with cannabinoids. Acta biologica Hungarica. vol 58 Suppl. 2008-04-02. PMID:18297798. |
the goal of this study was to evaluate whether acute treatments by endogenous cannabinoid agonist, selective cb1 or cb2 receptor antagonists modulate the expression of mu- (mor) and delta- (dor) opioid receptor mrna levels and functional activity in the cerebellum of transgenic mice deficient in the cb1 type of cannabis receptors. |
2008-04-02 |
2023-08-12 |
mouse |
| Estera Páldyová, E Bereczki, M Sántha, T Wenger, Anna Borsodi, S Benyh. Altered gene expression and functional activity of opioid receptors in the cerebellum of CB1 cannabinoid receptor knockout mice after acute treatments with cannabinoids. Acta biologica Hungarica. vol 58 Suppl. 2008-04-02. PMID:18297798. |
in addition, rimonabant (selective central cannabinoid cb1 receptor antagonist) and sr144528 (selective peripheral cannabinoid cb2 receptor antagonist) caused significant potentiation in mor functional activity in the wild-type animals, whereas dor mediated g-protein activation was increased in the cb1-/- mice. |
2008-04-02 |
2023-08-12 |
mouse |
| Itai A Ba. Regulation of skeletal remodeling by the endocannabinoid system. Annals of the New York Academy of Sciences. vol 1116. 2008-03-31. PMID:17646266. |
recently, the skeleton has been identified as a major endocannabinoid target through both the neuronal cb1 and predominantly peripheral cb2 cannabinoid receptors. |
2008-03-31 |
2023-08-12 |
mouse |
| Itai A Ba. Regulation of skeletal remodeling by the endocannabinoid system. Annals of the New York Academy of Sciences. vol 1116. 2008-03-31. PMID:17646266. |
since activation of cb2 attenuates experimentally induced bone loss by inhibiting bone resorption and stimulating bone formation, and because synthetic cannabinoids are stable and orally available, a therapy based on synthetic cb2 agonists is a promising novel target for antiosteoporotic drug development. |
2008-03-31 |
2023-08-12 |
mouse |
| Valeria Rettori, Javier Fernandez-Solari, Juan P Prestifilippo, Claudia Mohn, Andrea De Laurentiis, Stefan R Bornstein, Monika Ehrhart-Bornstein, Juan C Elverdin, Samuel M McCan. Endocannabinoids in TNF-alpha and ethanol actions. Neuroimmunomodulation. vol 14. issue 3-4. 2008-03-31. PMID:18073513. |
both cannabinoid receptors, cb1 and cb2, are localized in the submandibular gland where they mediate the inhibitory effect of intrasubmandibular injections of the endocannabinoid anandamide (6 x 10(-5)m) on salivary secretion. |
2008-03-31 |
2023-08-12 |
rat |
| Sören V Siegmund, Robert F Schwab. Endocannabinoids and liver disease. II. Endocannabinoids in the pathogenesis and treatment of liver fibrosis. American journal of physiology. Gastrointestinal and liver physiology. vol 294. issue 2. 2008-03-25. PMID:18006606. |
in the injured liver, the endocannabinoid system is upregulated both at the level of endocannabinoids and at the endocannabinoid receptors cb1 and cb2. |
2008-03-25 |
2023-08-12 |
Not clear |
| Sharon DeMorrow, Heather Francis, Eugenio Gaudio, Yoshiyuki Ueno, Julie Venter, Paolo Onori, Antonio Franchitto, Bradley Vaculin, Shelley Vaculin, Gianfranco Alpin. Anandamide inhibits cholangiocyte hyperplastic proliferation via activation of thioredoxin 1/redox factor 1 and AP-1 activation. American journal of physiology. Gastrointestinal and liver physiology. vol 294. issue 2. 2008-03-25. PMID:18096608. |
mrna expression of the cannabinoid receptors cb1 and vr1 was decreased after bdl, whereas there was an upregulation of cb2 mrna. |
2008-03-25 |
2023-08-12 |
mouse |
| Teresa Iuvone, Giuseppe Esposito, Daniele De Filippis, Tiziana Bisogno, Stefania Petrosino, Caterina Scuderi, Vincenzo Di Marzo, Luca Steard. Cannabinoid CB1 receptor stimulation affords neuroprotection in MPTP-induced neurotoxicity by attenuating S100B up-regulation in vitro. Journal of molecular medicine (Berlin, Germany). vol 85. issue 12. 2008-03-13. PMID:17639288. |
because mptp selectively increased the levels of anandamide in c6 cells, the involvement of the endocannabinoid system was investigated by using selective inhibitors of endocannabinoid inactivation (cellular re-uptake or enzymatic hydrolysis) and selective cannabinoid cb1 and cb2 receptor antagonists and by silencing the cb1 receptor. |
2008-03-13 |
2023-08-12 |
Not clear |
| E J Rahn, A Makriyannis, A G Hohman. Activation of cannabinoid CB1 and CB2 receptors suppresses neuropathic nociception evoked by the chemotherapeutic agent vincristine in rats. British journal of pharmacology. vol 152. issue 5. 2008-02-25. PMID:17572696. |
activation of cannabinoid cb1 and cb2 receptors suppresses neuropathic nociception evoked by the chemotherapeutic agent vincristine in rats. |
2008-02-25 |
2023-08-12 |
rat |
| J M McPartland, M Glass, R G Pertwe. Meta-analysis of cannabinoid ligand binding affinity and receptor distribution: interspecies differences. British journal of pharmacology. vol 152. issue 5. 2008-02-25. PMID:17641667. |
pooled data from 211 studies measured ligand binding affinities at human (hs) or rat (rn) cannabinoid receptors cb1 and cb2. |
2008-02-25 |
2023-08-12 |
human |
| M D Jhaveri, D Richardson, V Chapma. Endocannabinoid metabolism and uptake: novel targets for neuropathic and inflammatory pain. British journal of pharmacology. vol 152. issue 5. 2008-02-25. PMID:17704819. |
cannabinoid cb1 and cb2 receptors are located at key sites involved in the relaying and processing of noxious inputs. |
2008-02-25 |
2023-08-12 |
Not clear |
| S E O'Sulliva. Cannabinoids go nuclear: evidence for activation of peroxisome proliferator-activated receptors. British journal of pharmacology. vol 152. issue 5. 2008-02-25. PMID:17704824. |
cannabinoids act at two classical cannabinoid receptors (cb1 and cb2), a 7tm orphan receptor and the transmitter-gated channel transient receptor potential vanilloid type-1 receptor. |
2008-02-25 |
2023-08-12 |
Not clear |
| C R Hiley, S S Kau. GPR55 and the vascular receptors for cannabinoids. British journal of pharmacology. vol 152. issue 5. 2008-02-25. PMID:17704825. |
cb1 and cb2 receptors mediate most responses to cannabinoids but not some of the cardiovascular actions of endocannabinoids such as anandamide and virodhamine, or those of some synthetic agents, like abnormal cannabidiol (abn-cbd). |
2008-02-25 |
2023-08-12 |
mouse |
| D Baker, S J Jackson, G Pryc. Cannabinoid control of neuroinflammation related to multiple sclerosis. British journal of pharmacology. vol 152. issue 5. 2008-02-25. PMID:17891167. |
in experimental studies it has been recently shown that synthetic cannabinoids can affect the immune response both indirectly via cb1 receptor-mediated signalling nerve centres controlling the systemic release of immunosuppressive molecules and directly by cb2 receptor-mediated inhibition of lymphocyte and macrophage/microglial cell function. |
2008-02-25 |
2023-08-12 |
Not clear |
| A Mallat, S Lotersztaj. Endocannabinoids and liver disease. I. Endocannabinoids and their receptors in the liver. American journal of physiology. Gastrointestinal and liver physiology. vol 294. issue 1. 2008-02-21. PMID:17975129. |
cannabinoid receptors (cb1 and cb2) and their endogenous ligands (endocannabinoids) have recently emerged as novel mediators of liver diseases. |
2008-02-21 |
2023-08-12 |
Not clear |
| Douglas McHugh, Carolyn Tanner, Raphael Mechoulam, Roger G Pertwee, Ruth A Ros. Inhibition of human neutrophil chemotaxis by endogenous cannabinoids and phytocannabinoids: evidence for a site distinct from CB1 and CB2. Molecular pharmacology. vol 73. issue 2. 2008-02-19. PMID:17965195. |
inhibition of human neutrophil chemotaxis by endogenous cannabinoids and phytocannabinoids: evidence for a site distinct from cb1 and cb2. |
2008-02-19 |
2023-08-12 |
human |